Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice

Shock

Volumn 47, Issue 5, 2017, Pages 638-645

  Zhou, Yong ^a   Liu, Tian ^a   Duan, Jia Xi ^a   Li, Ping ^a   Sun, Guo Ying ^a   Liu, Yong Ping ^a   Zhang, Jun ^b   Dong, Liang ^c   Lee, Kin Sing Stephen ^d   Hammock, Bruce D ^d   Jiang, Jian Xin ^e   Guan, Cha Xiang ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c ZUNYI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute lung injury; epoxyeicosatrienoic acids; inflammation; lipopolysaccharide; soluble epoxide hydrolase inhibitor

Indexed keywords

EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; TRIFLUOROMETHOXYPHENYL PROPIONYLPIPERIDIN UREA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ANTIINFLAMMATORY AGENT; DIHOMO GAMMA LINOLENIC ACID; EPOXIDE HYDROLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY LEAK SYNDROME; CELL COUNTING; CONTROLLED STUDY; CYTOKINE RELEASE; DRY WEIGHT; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY; LUNG EDEMA; LUNG WEIGHT; MACROPHAGE; MALE; MORTALITY RATE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; SURVIVAL RATE; WESTERN BLOTTING; ACUTE LUNG INJURY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOLOGY; METABOLISM; PNEUMONIA; RAW 264.7 CELL LINE;

8,11,14-EICOSATRIENOIC ACID; ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; EPOXIDE HYDROLASES; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; NF-KAPPA B; PNEUMONIA; RAW 264.7 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84991510657     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000767     Document Type: Article

References (35)

1. Hsu AT, Barrett CD, DeBusk GM, Ellson CD, Gautam S, Talmor DS, Gallagher DC, Yaffe MB: Kinetics and role of plasma matrix metalloproteinase-9 expression in acute lung injury and the acute respiratory distress syndrome. Shock 44(2):128-136, 2015.
2. Standiford TJ, Ward PA: Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res 167(1):183-191, 2016.
3. Villar J, Blanco J, Anon JM, Santos-Bouza A, Blanch L, Ambros A, Gandia F, Carriedo D, Mosteiro F, Basaldua S, et al.: The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 37(12):1932-1941, 2011.
4. Liu H, Liang X, Wang D, Zhang H, Liu L, Chen H, Li Y, Duan Q, Xie K: Combination therapy with nitric oxide and molecular hydrogen in a murine model of acute lung injury. Shock 43(5):504-511, 2015.
5. Takashima K, Matsushima M, Hashimoto K, Nose H, Sato M, Hashimoto N, Hasegawa Y, Kawabe T: Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury. Respir Res 15(1):150, 2014.
6. Harris TR, Hammock BD: Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526(2):61-74, 2013.
7. Bettaieb A, Chahed S, Bachaalany S, Griffey S, Hammock BD, Haj FG: Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental acute pancreatitis in mice. Mol Pharmacol 88(2):281-290, 2015.
8. Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ: Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol 308(2):F131-F139, 2015.
9. Imig JD, Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8(10):794-805, 2009.
10. Zhou Y, Sun GY, Liu T, Duan JX, Zhou HF, Lee KS, Hammock BD, Fang X, Jiang JX, Guan CX: Soluble epoxide hydrolase inhibitor 1-trifluoromethox-yphenyl-3-(1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. Cell Tissue Res 363(2):399-409, 2016.
11. Yang J, Bratt J, Franzi L, Liu JY, Zhang G, Zeki AA, Vogel CF, Williams K, Dong H, Lin Y, et al.: Soluble epoxide hydrolase inhibitor attenuates inflam-mation and airway hyperresponsiveness in mice. Am J Respir Cell Mol Biol 52(1):46-55, 2015.
12. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD: Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 102(6):2186-2191, 2005.
13. Baudiss K, de Paula Vieira R, Cicko S, Ayata K, Hossfeld M, Ehrat N, Gomez-Munoz A, Eltzschig HK, Idzko M: C1P attenuates lipopolysaccharide-induced acute lung injury by preventing nf-kappab activation in neutrophils. J Immunol 196(5):2319-2326, 2016.
14. Yang J, Schmelzer K, Georgi K, Hammock BD: Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81(19):8085-8093, 2009.
15. Qi D, He J, Wang D, Deng W, Zhao Y, Ye Y, Feng L: 17beta-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo and in vitro. Respir Res 15(1):159, 2014.
16. Gonzales JN, Gorshkov B, Varn MN, Zemskova MA, Zemskov EA, Sridhar S, Lucas R, Verin AD: Protective effect of adenosine receptors against lipopoly-saccharide-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 306(6):L497-507, 2014.
17. King BA, Kingma PS: Surfactant protein D deficiency increases lung injury during endotoxemia. Am J Respir Cell Mol Biol 44(5):709-715, 2011.
18. Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M: Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat 120:80-90, 2015.
19. Du J, Li X, Lin C, He X: Protective effects of arachidonic acid against paraquat-induced pulmonary injury. Inflammation 38(4):1458-1463, 2015.
20. Wang W, Zhu J, Lyu F, Panigrahy D, Ferrara KW, Hammock B, Zhang G: omega-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer. Prostaglandins Other Lipid Mediat 113-115:13-20, 2014.
21. Patrignani P, Patrono C: Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta 1851(4):422-432, 2015.
22. Radmark O, Werz O, Steinhilber D, Samuelsson B: 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim Biophys Acta 1851(4):331-339, 2015.
23. Li L, Li N, Pang W, Zhang X, Hammock BD, Ai D, Zhu Y: Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLoS One 9(4):e94092, 2014.
24. Node K, Huo YQ, Ruan XL, Yang BC, Spiecker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eico-sanoids. Science 285(5431):1276-1279, 1999.
25. Hecker A, Kullmar M, Wilker S, Richter K, Zakrzewicz A, Atanasova S, Mathes V, Timm T, Lerner S, Klein J, et al.: Phosphocholine-modified macromolecules and canonical nicotinic agonists inhibit atp-induced il-1beta release. J Immunol 195(5):2325-2334, 2015.
26. Jones HD, Crother TR, Gonzalez-Villalobos RA, Jupelli M, Chen S, Dagvadorj J, Arditi M, Shimada K: The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. Am J Respir Cell Mol Biol 50(2):270-280, 2014.
27. Grailer JJ, Canning BA, Kalbitz M, Haggadone MD, Dhond RM, Andjelkovic AV, Zetoune FS, Ward PA: Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol 192(12):5974-5983, 2014.
28. Han S, Cai W, Yang X, Jia Y, Zheng Z, Wang H, Li J, Li Y, Gao J, Fan L, et al.: ROS-mediated NLRP3 inflammasome activity is essential for burn-induced acute lung injury. Mediators Inflamm 2015:720457, 2015.
29. Fukumoto J, Fukumoto I, Parthasarathy PT, Cox R, Huynh B, Ramanathan GK, Venugopal RB, Allen-Gipson DS, Lockey RF, Kolliputi N: NLRP3 deletion protects from hyperoxia-induced acute lung injury. Am J Physiol Cell Physiol 305(2):C182-C189, 2013.
30. Zhang Y, Li X, Grailer JJ, Wang N, Wang M, Yao J, Zhong R, Gao GF, Ward PA, Tan DX, et al.: Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res 13(2):148-159, 2016.
31. Galam L, Rajan A, Failla A, Soundararajan R, Lockey RF, Kolliputi N: Deletion of P2X7 attenuates hyperoxia-induced acute lung injury via inflammasome suppression. Am J Physiol Lung Cell Mol Physiol 310(6):L572-L581, 2016.
32. Jo EK, Kim JK, Shin DM, Sasakawa C: Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13(2):148-159, 2016.
33. Chen W, Zheng G, Yang S, Ping W, Fu X, Zhang N, Wang DW, Wang J: CYP2J2 and EETs protect against oxidative stress and apoptosis in vivo and in vitro following lung ischemia/reperfusion. Cell Physiol Biochem 33(6):1663-1680, 2014.
34. Morisseau C, Hammock BD: Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53:37-58, 2013.
35. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK: Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single-and multiple-dose studies in healthy human subjects. J Clin Pharmacol 52(3):319-328, 2012.